Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. (Q52890142)

From Wikidata

Jump to navigation Jump to search

scientific article published on 17 January 2012

Language	Label	Description	Also known as
English	Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.	scientific article published on 17 January 2012

Statements

scholarly article

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/22257523

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. (English)

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/22257523

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Peter A. Fasching

9

object named as

Peter A Fasching

1 reference

Europe PubMed Central

9 May 2018

2

object named as

Sibylle Loibl

1 reference

Europe PubMed Central

9 May 2018

1

object named as

Michael Untch

1 reference

Europe PubMed Central

9 May 2018

author name string

Joachim Bischoff

3

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/22257523

Holger Eidtmann

4

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/22257523

Manfred Kaufmann

5

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/22257523

Jens-Uwe Blohmer

6

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/22257523

Jörn Hilfrich

7

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/22257523

Dirk Strumberg

8

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/22257523

Rolf Kreienberg

10

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/22257523

Hans Tesch

11

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/22257523

Claus Hanusch

12

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/22257523

Bernd Gerber

13

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/22257523

Mahdi Rezai

14

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/22257523

Christian Jackisch

15

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/22257523

Jens Huober

16

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/22257523

Thorsten Kühn

17

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/22257523

Valentina Nekljudova

18

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/22257523

Gunter von Minckwitz

19

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/22257523

German Breast Group (GBG)

20

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/22257523

Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group

21

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/22257523

publication date

17 January 2012

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/22257523

Lancet Oncology Commission

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/22257523

13

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/22257523

2

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/22257523

135-144

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/22257523

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970397-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970397-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970397-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970397-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970397-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970397-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970397-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970397-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970397-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970397-7

7 January 2021

based on heuristic

inferred from DOI database lookup

[Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy]

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970397-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Patterns of treatment effects in subsets of patients in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970397-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970397-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970397-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970397-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970397-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970397-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970397-7

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (H

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970397-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(11)70397-7

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/22257523

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/22257523

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52890142&oldid=1561175298"